S&P removes drugmaker Wyeth from 2 indices in sign $68B acquisition by Pfizer will go throughOctober 2nd, 2009 S&P removes Wyeth from indices before acquisitionTRENTON, N.J. — In the latest sign that Pfizer Inc.'s $68 billion purchase of Wyeth will go through, Wyeth's stock has been removed from two key investor indices.
Pfizer's $68 billion buyout of Wyeth gets clearance in Australia, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in AustraliaNEW YORK — Drug developer Pfizer says the Australian Competition and Consumer Commission approved the company's $68 billion buyout of rival Wyeth. Pfizer will divest certain animal health assets in Australia, the New York-based company says.
Pfizer's $68 billion buyout of Wyeth gets clearance in China, still awaiting US clearanceSeptember 30th, 2009 Pfizer, Wyeth deal gets clearance in ChinaNEW YORK — Drug developer Pfizer Inc. said Tuesday China's ministry of commerce approved the company's $68 billion buyout of rival Wyeth.
Wyeth calls for redemption of floating rate convertible senior debenturesAugust 17th, 2009 Wyeth calls for redemption of senior debenturesMADISON, N.J. — Drugmaker Wyeth said Monday it has called for the full redemption of its outstanding floating rate convertible senior debentures due in 2024 on Sept.
Merck & Co. shareholders OK $41.1 billion acquisition of partner drugmaker Schering-PloughAugust 7th, 2009 Merck shareholders OK Schering-Plough purchaseTRENTON, N.J. — Shareholders of drugmaker Merck & Co.
Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck.
Drugmaker Wyeth posts 13 percent jump in 2Q profit on cost cutting ahead of Pfizer acquisitionJuly 23rd, 2009 Drugmaker Wyeth posts 13 percent jump in 2Q profitTRENTON, N.J. — Drugmaker Wyeth on Thursday posted a 13 percent jump in second-quarter profit, trouncing Wall Street forecasts, as cost cuts overcame lower sales due to generic competition and the strong dollar.
Drugmaker Pfizer's 2Q profit plunges 19 percent on Wyeth acquisition charges, stronger dollarJuly 22nd, 2009 Drugmaker Pfizer's 2Q profit plunges 19 percentTRENTON, N.J. — Drug giant Pfizer Inc.
98 percent of shareholders of drugmaker Wyeth vote to be acquired by industry giant PfizerJuly 20th, 2009 Wyeth shareholders vote to be acquired by PfizerTRENTON, N.J. — Shareholders of drugmaker Wyeth on Monday voted overwhelmingly to be bought by industry giant Pfizer Inc., pushing aside one of the deal's final hurdles.
Wyeth says regulators in Chile grant 1st marketing approval to new type of Prevnar vaccineJuly 14th, 2009 Wyeth says Chile approves Prevnar 13 vaccineCOLLEGEVILLE, Pa. — Wyeth on Tuesday reported the first marketing approval for a new version of its vaccine Prevnar, as the drug was cleared by regulators in Chile.
Pfizer pulls out of plan to move biotech workers to San Francisco facilityJuly 7th, 2009 Pfizer ends plan San Francisco biotech facilityNEW YORK — Pfizer Inc. is pulling a plan to staff a biotechnology research center in San Francisco and will keep its 100 area employees in South San Francisco.
EU says Pfizer is suggesting changes to Wyeth bid to win regulatory approvalJune 30th, 2009 EU: Pfizer promising changes to Wyeth bidBRUSSELS — U.S. drug maker Pfizer Inc.
Drugmaker Wyeth sets July annual meeting for shareholders to vote on acquisition by PfizerJune 18th, 2009 Wyeth sets meeting for shareholders' merger voteMORRISTOWN, N.J. — Wyeth has scheduled a meeting for the drugmaker's shareholders to vote whether to approve its pending acquisition by drug giant Pfizer.
Drugmaker Pfizer's Q1 profit dips 2 percent on much lower sales, costs of Wyeth acquisitionApril 28th, 2009 Pfizer profit dips 2 percent, sales fall much moreNEW YORK — Pfizer Inc. posts a 2 percent drop in first-quarter profit, as cost-cutting by the world's largest drugmaker couldn't offset big drops in sales for several medicines.
Pfizer offers Rs.6.8 bn to raise stake in Indian armApril 13th, 2009 MUMBAI - Global pharmaceutical major Pfizer Monday said it will make an offer to acquire a further 33.77 percent in its Indian subsidiary Pfizer Ltd for Rs.6.8 billion. The acquisition will raise its stake to 75 percent.
Loading ...